KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Abstract Background KRAS-G12C inhibitors mark a notable advancement in targeted cancer therapies, yet identifying predictive biomarkers for treatment efficacy and resistance remains essential for optimizing clinical outcomes. Methods This systematic meta-analysis synthesized studies available throug...

Descripció completa

Dades bibliogràfiques

Autors principals:	Linyan Tian, Chengming Liu, Sufei Zheng, Huiyang Shi, Fang Wei, Wenxin Jiang, Yucheng Dong, Haiyan Xu, Enzhi Yin, Nan Sun, Jie He, Yan Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-01-01
Col·lecció:	Journal of Translational Medicine
Matèries:	KRAS-G12C inhibitors KEAP1 mutations Biomarkers Drug resistance Targeted therapy
Accés en línia:	https://doi.org/10.1186/s12967-025-06089-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!